RecruitingNCT04185779
COLO-COHORT (Colorectal Cancer Cohort) Study
Sponsor
South Tyneside and Sunderland NHS Foundation Trust
Enrollment
15,000 participants
Start Date
Dec 13, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
This is a cross-sectional study aimed at identifying factors which best predicts patients at high risk of colorectal cancer or colorectal adenomas and to develop a risk prediction model.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is building a large observational database (cohort) of people undergoing colonoscopy, to better understand the risk factors, early detection, and natural history of colorectal cancer. It includes both people who have cancer detected and those who don't.
**You may be eligible if...**
- You are 30 years or older and can give informed consent
- You are attending for a colonoscopy (through cancer screening, NHS referral, surveillance, or for symptoms like rectal bleeding or iron deficiency anemia)
- OR you are a first-degree relative of someone with colorectal cancer (for a separate cohort)
**You may NOT be eligible if...**
- You have a known inflammatory bowel disease (Crohn's or ulcerative colitis)
- You have a hereditary colon cancer syndrome (e.g., Lynch syndrome, familial adenomatous polyposis)
- You have previously had colorectal cancer
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTColonoscopy
Diagnostic colonoscopy
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04185779
Related Trials
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT0706665720 locations
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT0697411015 locations
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT0752520627 locations
IDOV-Immune for Advanced Solid Tumors
NCT069106575 locations
The Florida ASCENT Study
NCT070422431 location